Spots Global Cancer Trial Database for An Investigation of TAS-119 Monotherapy
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: An Investigation of TAS-119 Monotherapy
Official Title: A Phase I, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of TAS-119 in Patients With Advanced Solid Tumors
Study ID: NCT02448589
Conditions
Interventions
Study Description
Brief Summary: A Phase 1, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of TAS-119 in Patients with Advanced Solid Tumors.
Detailed Description: This is a Phase 1, open-label, non-randomized, dose escalation study of TAS-119 evaluating the safety, tolerability, PK, pharmacogenomics, pharmacodynamics, and preliminary antitumour activity in patients with advanced and unresectable solid tumours. The study will evaluate TAS-119 monotherapy, employing two sequential phases. * A Dose Escalation Phase * An Expansion Phase
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University Hospitals - Seidman Cancer Center, Cleveland, Ohio, United States
San Raffaele Hospital, Milano, , Italy
Erasmus MC Cancer Institute, Rotterdam, , Netherlands
START MADRID-FJD, Hospital Fundación Jiménez Díaz, Madrid, , Spain
START Madrid Unidad de Ensayos Fase I, Madrid, , Spain
The Institute of Cancer Research, Sutton, Surrey, United Kingdom
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
